Latest news with #RocheHoldingAG
Globe and Mail
6 hours ago
- Business
- Globe and Mail
Deutsche Bank Reaffirms Their Sell Rating on Roche Holding AG (RHHVF)
In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Sell rating on Roche Holding AG, with a price target of CHF235.00. The company's shares closed yesterday at $321.46. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Papadakis is a 4-star analyst with an average return of 3.5% and a 51.43% success rate. Papadakis covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Novartis AG, and AstraZeneca. In addition to Deutsche Bank , Roche Holding AG also received a Sell from J.P. Morgan's Richard Vosser in a report issued yesterday. However, on July 17, Berenberg Bank maintained a Hold rating on Roche Holding AG (Other OTC: RHHVF). The company has a one-year high of $354.19 and a one-year low of $269.80. Currently, Roche Holding AG has an average volume of 11.61K.
Bloomberg
3 days ago
- Health
- Bloomberg
Roche Suffers Setback as Lung Drug Gets Mixed Result in Trial
Roche Holding AG 's experimental drug for a deadly lung condition got mixed results in trials, a setback as the company seeks to accelerate the development of new treatments. The late-stage trials for astegolimab — the medicine being developed to treat chronic obstructive pulmonary disease, or COPD — offered contrasting results, according to a statement on Monday.
Business Insider
12-07-2025
- Business
- Business Insider
Kepler Capital Remains a Buy on Roche Holding AG (RHHVF)
In a report released on July 10, David Evans from Kepler Capital maintained a Buy rating on Roche Holding AG, with a price target of CHF315.00. The company's shares closed yesterday at $324.49. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Evans is a 2-star analyst with an average return of 0.4% and a 57.00% success rate. Evans covers the Healthcare sector, focusing on stocks such as Roche Holding AG, Novo Nordisk, and Novartis AG. Currently, the analyst consensus on Roche Holding AG is a Hold with an average price target of $358.94, a 10.62% upside from current levels. In a report released on July 10, UBS also maintained a Buy rating on the stock with a CHF314.00 price target.
Business Insider
18-06-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Kuros Biosciences (OtherCSBTF), CSL (OtherCMXHF) and Roche Holding AG (OtherRHHVF)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Kuros Biosciences (CSBTF – Research Report), CSL (CMXHF – Research Report) and Roche Holding AG (RHHVF – Research Report) with bullish sentiments. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Kuros Biosciences (CSBTF) Kepler Capital analyst Christophe dombu maintained a Buy rating on Kuros Biosciences on June 16 and set a price target of CHF32.50. The company's shares closed last Wednesday at $33.22, close to its 52-week high of $36.10. According to dombu is ranked #8486 out of 9621 analysts. The the analyst consensus on Kuros Biosciences is currently a Hold rating. CSL (CMXHF) Morgan Stanley analyst David Bailey maintained a Buy rating on CSL today and set a price target of A$303.00. The company's shares closed last Tuesday at $148.56. According to Bailey is a 4-star analyst with an average return of 16.4% and a 48.1% success rate. Bailey covers the Healthcare sector, focusing on stocks such as Fisher & Paykel Healthcare Corporation Limited, Ramsay Health Care, and Cochlear. CSL has an analyst consensus of Strong Buy, with a price target consensus of $203.87, implying a 37.2% upside from current levels. In a report released yesterday, Jarden also maintained a Buy rating on the stock with a A$317.61 price target. Roche Holding AG (RHHVF) Kepler Capital analyst David Evans maintained a Buy rating on Roche Holding AG on June 16 and set a price target of CHF315.00. The company's shares closed last Tuesday at $321.13. According to Evans is ranked #4919 out of 9621 analysts. The word on The Street in general, suggests a Hold analyst consensus rating for Roche Holding AG with a $352.85 average price target, implying an 8.3% upside from current levels. In a report issued on June 16, UBS also maintained a Buy rating on the stock with a CHF314.00 price target.
Yahoo
15-05-2025
- Business
- Yahoo
Avastin (Bevacizumab) Market Research Report 2025: Epidemiology, Pipeline Analysis, Insights & Forecasts 2019-2024, 2024-2029F, 2034F
Key player operating in the avastin (bevacizumab) market is Roche Holding AG. North America was the largest region in the avastin (bevacizumab) market in 2024. The regions covered in avastin (bevacizumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the avastin (bevacizumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Dublin, May 15, 2025 (GLOBE NEWSWIRE) -- The "Avastin (Bevacizumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to Avastin (Bevacizumab) market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the growth during the historical period can be attributed to factors such as regulatory approvals, rising cancer prevalence, clinician adoption, expanding indication approvals, and favorable reimbursement growth during the forecast period is driven by increased awareness, earlier diagnosis, biosimilar competition, the rise of personalized medicine, improved healthcare accessibility, and a growing focus on precision medicine. Key trends for the forecast period include the rise of combination therapies, a shift towards outpatient care, patient-centric treatment models, increased adoption of targeted therapies, and ongoing product increasing prevalence of cancer is expected to drive the growth of the avastin (bevacizumab) market in the coming years. Cancer encompasses a group of diseases characterized by the uncontrolled growth and spread of abnormal cells. The rising incidence of cancer can be attributed to factors such as aging populations, lifestyle changes, and advancements in detection methods. Avastin, a monoclonal antibody, treats cancer by inhibiting VEGF, preventing the formation of blood vessels that supply oxygen and nutrients to tumors, thereby impeding tumor growth. For instance, the American Cancer Society reported that in 2022, approximately 1.9 million new cancer cases and 609,360 cancer-related deaths were anticipated in the United States, equivalent to about 1,670 deaths daily. This rising cancer burden is a significant driver of the avastin market's growth of the Avastin (bevacizumab) market is expected to be propelled by rising healthcare expenditure. Healthcare expenditure encompasses the total spending on health-related goods and services, including personal care, preventive measures, and public health activities, aimed at enhancing health outcomes. This increase is driven by factors such as an aging population, the prevalence of chronic diseases, advancements in medical technology, high drug prices, inefficient payment systems, and a growing demand for healthcare services. Elevated healthcare expenditure facilitates greater access to Avastin through improved insurance coverage, thereby broadening its market reach and patient utilization. For example, a report by the UK's Office for National Statistics in May 2024 highlighted a 5.6% nominal increase in total healthcare expenditure from 2022 to 2023, compared to a 0.9% growth rate in 2022. Additionally, long-term health and social care spending rose by 2.8% in real terms in 2022. This trend reflects how increasing investment in healthcare systems supports the accessibility and growth of innovative treatments like Avastin, further driving the market forward.A key trend shaping the avastin (bevacizumab) market is the development of biosimilars to provide cost-effective alternatives and improve access to cancer treatments. Biosimilars, highly similar in structure, function, and efficacy to Avastin, are transforming oncology care by offering affordable options, particularly in resource-constrained settings. For example, in October 2022, Amneal Pharmaceuticals launched ALYMSYS (bevacizumab-maly), a biosimilar referencing Avastin, in the U.S. This VEGF inhibitor is indicated for various cancers, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, renal cell carcinoma, and gynecologic cancers, demonstrating the potential of biosimilars to enhance treatment (bevacizumab) is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), effectively inhibiting angiogenesis - the process by which new blood vessels are formed to supply tumors with oxygen and nutrients. It is commonly used in conjunction with chemotherapy to treat various cancers, including colorectal, lung, kidney, and primary dosages of avastin (bevacizumab) are 100 mg and 400 mg. The 100 mg dosage form is used to treat a range of cancers by preventing the growth of blood vessels that nourish tumors. Its applications include non-squamous non-small cell lung cancer, recurrent glioblastoma, cervical cancer, colorectal cancer, ovarian cancer, proliferative diabetic retinopathy, malignant glioma, neurofibromatosis, pancreatic cancer, among others. These products are distributed through various channels such as direct tender, hospital pharmacies, retail pharmacies, and online pharmacies. End users include hospitals, cancer care centers, home healthcare providers, academic and research institutes, and avastin (bevacizumab) market consists of sales of intravenous (iv) formulations, and bevacizumab injection. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the Topics Covered: 1. Executive Summary2. Avastin (Bevacizumab) Market Characteristics3. Avastin (Bevacizumab) Market Biologic Drug Characteristics3.1. Molecule Type3.2. Route of Administration (ROA)3.3. Mechanism of Action (MOA)3.4. Safety and Efficacy4. Avastin (Bevacizumab) Market Trends and Strategies5. Avastin (Bevacizumab) Market - Macro Economic Scenario Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market6. Global Avastin (Bevacizumab) Growth Analysis and Strategic Analysis Framework6.1. Global Avastin (Bevacizumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)6.2. Analysis of End Use Industries6.3. Global Avastin (Bevacizumab) Market Growth Rate Analysis6.4. Global Avastin (Bevacizumab) Historic Market Size and Growth, 2019-2024, Value ($ Billion)6.5. Global Avastin (Bevacizumab) Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Billion)6.6. Global Avastin (Bevacizumab) Total Addressable Market (TAM)7. Global Avastin (Bevacizumab) Market Pricing Analysis & Forecasts8. Avastin (Bevacizumab) Market Segmentation8.1. Global Avastin (Bevacizumab) Market, Segmentation by Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion 100 Mg 400 Mg 8.2. Global Avastin (Bevacizumab) Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Non Squamous Non-Small Cell Lung Cancer Recurrent Glioblastoma Cervical Cancer Colorectal Cell Cancer Ovarian Cancer Proliferative Diabetic Retinopathy Malignant Glioma Neurofibromatosis Pancreatic Cancer Other Applications 8.3. Global Avastin (Bevacizumab) Market, Segmentation by Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Direct Tender Hospital Pharmacy Retail Pharmacy Online Pharmacy Other Distribution Channels 8.4. Global Avastin (Bevacizumab) Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Hospitals Cancer Supportive Centers Home Healthcare Academic and Research Institutes Other End Users 9. Global Avastin (Bevacizumab) Market Epidemiology of Clinical Indications9.1. Drug Side Effects9.2. Incidence and Prevalence of Clinical Indications10. Avastin (Bevacizumab) Market Regional and Country Analysis10.1. Global Avastin (Bevacizumab) Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion10.2. Global Avastin (Bevacizumab) Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
